Investigation of Thioredoxin-1 Family Protein Expression in Rectal Cancer
- Determine expression levels of thioredoxin-1 (Trx-1), thioredoxin-interacting protein
(TXNIP), and hypoxia inducible factor-1 alpha (HIF-1α) in paraffin-embedded resected
tumor tissue samples from patients with stage II or III rectal cancer enrolled in
clinical trial SWOG-9304.
- Determine if there is a correlation between Trx-1 and TXNIP expression and HIF-1α
- Correlate expression of these proteins with tumor stage, disease-free survival, overall
survival, and risk of recurrence.
- Determine interactions for patient age, performance status, and type of therapy
received on clinical trial SWOG-9304.
OUTLINE: This is a multicenter study.
Paraffin-embedded resected tumor tissue samples are analyzed for protein expression levels
(thioredoxin-1, thioredoxin-interacting protein, and hypoxia inducible factor-1 alpha) by
tissue microarray and immunostaining.
Observational Model: Cohort, Time Perspective: Retrospective
Expression of thioredoxin-1, thioredoxin-interacting protein, and hypoxia inducible factor-1 alpha
upon testing of specimens
Tomislav Dragovich, MD, PhD
University of Arizona
United States: Federal Government